# Ixazomib Rollover Study

> **NCT02924272** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma
- Lymphoma
- Amyloidosis

## Interventions

- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT02924272
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-16
- **Primary completion:** 2024-07-03
- **Final completion:** 2024-07-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924272, "Ixazomib Rollover Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02924272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*